Claret Capital Partners
Venture debtLondon · Series A–Late Stage · 28 people tracked
Investment thesis
Claret Capital Partners provides venture debt financing to growth-stage companies across Europe, positioning debt as a complement to equity within the capital stack. The firm backs businesses in technology, life sciences/therapeutics, healthtech, fintech/payments, space and impact sectors, offering flexible non-dilutive funding to support expansion. It has deployed more than €1.5bn across over 200 companies, extending financings that range from single-digit to tens of millions of euros, often alongside equity investors and as follow-on support for existing portfolio companies.
Source: firm website, verified Aug 3, 2026.
Team · 28 people
from the firm's websiteWhat they invest in
from 10 of 32 portfolio companiesSaaS ×4AI & Machine Learning ×3Biotech ×2Healthtech ×2Medical Devices ×2Sports Tech ×2B2B Marketplaces ×1Consumer ×1
HQs:Germany×1Spain×1United Kingdom×1
Investments · 32 tracked
founders shown can be your intro pathU.S.-based company backed by Claret Capital Partners.
European late-stage biotech backed by Claret.
Cytora is a risk digitization and automation platform for commercial insurance that uses AI to help brokers, insurers, and reinsurers receive, process, and make decisions on risk submissions.
AI & Machine LearningInsurTech
Medical company backed via a debt funding deal.
Playtomic is an app and platform for racket sports (padel and tennis) that lets players find and book courts, connect with other players, track their progress, and join matches.
ConsumerMarketplacesSports Tech
Quantilope is a market research platform that combines research automation, AI intelligence, and real-time consumer insights to help companies gather actionable feedback and make data-driven decisions.
AI & Machine LearningMarketing TechSaaS
Medical company marking Claret's 200th portfolio company.
Wellster is a telemedicine platform that delivers digital medical care through synchronous and asynchronous consultations, guided by medical standards and supported by real-world evidence from anonymized treatment data.
Digital HealthHealthtech
Generative AI platform for life sciences and pharma that received €10M in growth funding from Claret.
Zen Educate operates a digital platform connecting schools to qualified substitute teachers and temporary educators.
B2B MarketplacesEdTechHR TechSaaSLondon, GB
Exits · 1
IPOs and acquisitions across the tracked portfolioCytoraacq. by Applied Systems
Principals & officers · per Companies House
what is this? ⓘDirector · Irish · since 2020
Director · British · since 2022
Director · Swedish · since 2020
Director · British · since 2026
Johan Mikael Kampe — 25–50% of shares, 25–50% of voting rights
David James Bateman — 25–50% of shares, 25–50% of voting rights
Frequently asked questions
- What stage does Claret Capital Partners invest at?
- Claret Capital Partners invests at the Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Claret Capital Partners focus on?
- Claret Capital Partners focuses on AI & Machine Learning, Biotech, Digital Health, Energy, Fintech, Healthtech, Impact & Social Good, Medical Devices, Space Tech.
- Where is Claret Capital Partners located?
- Claret Capital Partners is headquartered in London, GB.
Images
Similar investors
MDI Ventures is the corporate venture capital arm of Indonesia's Telkom Group, investing in technology startups and emphasizing measurable social and environmental impact alongside financial returns.
Amadeus Capital Partners is a deep tech investor backing companies across the themes of Intelligence, Human potential, and the Planet.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
Khosla Ventures is a venture capital firm known for backing bold, contrarian bets in world-class teams that can reshape entire industries.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.


















